+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Urokinase plasminogen activator in serous ovarian tumors Translocation of mRNA expression from the epithelium in benign and well differentiated to the stroma in poorly differentiated tumors



Urokinase plasminogen activator in serous ovarian tumors Translocation of mRNA expression from the epithelium in benign and well differentiated to the stroma in poorly differentiated tumors



Fibrinolysis 10(Suppl. 3): 115




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144160

Download citation: RISBibTeXText


Related references

High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. International Journal of Cancer 79(6): 588-595, 1998

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). International Journal of Cancer 92(4): 497-502, 2001

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. International Journal of Cancer 69(6): 475-479, 1996

Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clinical Chemistry and Laboratory Medicine 37(1): 47-54, 1999

Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20(47): 6965-6969, 18 October, 2001

Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Science 101(4): 1059-1066, 2010

Paratesticular cystadenomas with ovarian stroma, metaplastic serous mullerian epithelium, and male adnexal tumor of probable wolffian origin A series of 5 hitherto poorly recognized testicular tumors. 2012

Paratesticular cystadenomas with ovarian stroma, metaplastic serous Müllerian epithelium, and male adnexal tumor of probable wolffian origin: A series of 5 hitherto poorly recognized testicular tumors. Annals of Diagnostic Pathology 17(2): 151-158, 2013

Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. American Journal of Surgical Pathology 32(11): 1667-1674, 2008

Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. International Journal Of Cancer. 64(3): 171-175, 1995

Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. Anticancer Research 28(3b): 1905-1910, 2008

Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases. Virchows Archiv 465(1): 49-55, 2014

Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26(6): 1406-1413, 2008

Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. Journal of Clinical Oncology 23(29): 7257-7264, 2005

Plasminogen activator from benign ovarian tumors. Haemostasis 11(Suppl. 1): 41, 1982